anonymous
Guest
anonymous
Guest
Good luck to everyone who made the effort at a place where strategy continually shifted or was abandoned because it didn’t meet the short-sighted expectations of its leaders or the board. Access was doomed from the start. Patient type was really never clear and being the most recent to market with no access and no clear differentiator pounded a futile and changing message into the ground with weak results. Leadership changes have been non-stop from the top down and there has been a lack of consistency across the board. People came here for the small pharma experience but the past 8 months of newly hired leadership have been an unsuccessful effort to make this company big pharma, without the backing. So, let’s see how this company steps up and takes care of the people it discards and retains. They haven’t done it yet so here’s an opportunity.